Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,887.17 +2,210.70 (+3.37%) CMC Crypto 200
1,375.67 +45.07 (+3.39%)
BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
| Previous close | 7.55 |
| Open | 7.69 |
| Bid | 7.79 x 600 |
| Ask | 7.87 x 1400 |
| Day's range | 7.52 - 7.87 |
| 52-week range | 4.03 - 7.88 |
| Volume | |
| Avg. volume | 3,583,995 |
| Market cap | 1.62B |
| Beta (5Y monthly) | 1.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.00 |
GlobeNewswireBioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A l
ZacksBioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ZacksWall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
